Skip to main content

Table 1 Clinical characteristics of the patients from multiple institutions

From: m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer

Characteristics International cohort (N = 68) Shanghai cohort (N = 47) NCC cohort (N = 150)
Age, years
 < 60 16 (23.53%) 26 (55.32%) 81 (54.00%)
 ≥ 60 52 (76.47%) 21 (44.68%) 69 (46.00%)
Sex
 Male 48 (70.59%) 42 (89.36%) 119 (79.33%)
 Female 20 (29.41%) 5 (10.64%) 31 (20.67%)
Smoking history
 Yes 64 (94.12%) 32 (68.09%) 94 (62.67%)
 No 3 (4.41%) 15 (31.91%) 56 (37.33%)
 NA 1 (1.47%) 0 (0.00%) 0 (0.00%)
SCLC staging
 I 33 (48.53%) 8 (17.02%) 49 (32.67%)
 II 14 (20.59%) 39 (17.02%) 50 (33.33%)
 III 21 (30.88%) 31 (65.96%) 51 (34.00%)
OS state
 Alive 28 (41.18%) 24 (51.06%) 69 (46.00%)
 Death 40 (58.82%) 23 (48.94%) 81 (54.00%)
  1. Data are n (%).
  2. NCC, National Cancer Center; NA, not available; SCLC, small cell lung cancer; OS, overall survival